Damian Clarke-Bruce
Chief Executive Officer at HaemaLogiX Pty Ltd.
Net worth: 5 556 $ as of 2024-04-29
Profile
Damian Clarke-Bruce is currently the Chief Executive Officer & Managing Director at HaemaLogiX Pty Ltd.
He was previously the Chief Executive Officer, MD & Director at Race Oncology Ltd.
and the Executive Director-Global Marketing at Pharming Group NV.
Mr. Clarke-Bruce has an undergraduate degree from The University of New South Wales, a graduate degree from Macquarie University, and a graduate degree from The University of Sydney.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0.00% | 2023-08-20 | 6,818 ( 0.00% ) | 5 556 $ | 2024-04-29 |
Damian Clarke-Bruce active positions
| Companies | Position | Start |
|---|---|---|
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Chief Executive Officer | 2023-11-12 |
Former positions of Damian Clarke-Bruce
| Companies | Position | End |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Executive Officer | 2023-08-21 |
| PHARMING GROUP N.V. | Sales & Marketing | 2022-12-31 |
Training of Damian Clarke-Bruce
| The University of New South Wales | Undergraduate Degree |
| Macquarie University | Graduate Degree |
| The University of Sydney | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| RACE ONCOLOGY LIMITED | Health Technology |
| PHARMING GROUP N.V. | Health Technology |
| Private companies | 1 |
|---|---|
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
- Stock Market
- Insiders
- Damian Clarke-Bruce
